

The exercise period for Amniotics' warrants of series TO1 commences today

Amniotics AB (publ) ("Amniotics" or the "Company") conducted a unit issue of shares and warrants of series TO1 (the "warrants") in connection with the listing on Nasdaq First North Growth Market on July 6, 2021. The exercise period for the warrants commences today, May 5, 2022, and runs up to and including May 19, 2022. One (1) warrant entitles the holder to subscribe for one (1) new share in Amniotics. The subscription price per share that is subscribed for through exercising the warrants has, in accordance with the terms and conditions for the warrants, been set to SEK 23.50. If all warrants are exercised, Amniotics will receive approximately SEK 34.4 million before issuing costs.

Summary of instructions and important dates

Holders of warrants who wish to exercise these to subscribe for shares shall give notice regarding such exercise well before May 19, 2022. Warrants that have not been exercised on or before May 19, 2022, expire without value. Holders who do not wish to exercise their warrants may sell them. Trading with warrants is ongoing up to and including May 17, 2022.

Detailed information and instructions for subscription

Exercise of nominee-registered warrants

Holders of warrants who have their holdings nominee-registered (holdings in securities custody services, investment savings accounts (ISK) or endowment insurances) must notify the exercise of warrants by contacting their respective nominee and follow the nominee's instructions regarding subscription and payment. This should take place well before May 19, 2022, as different nominees have different processing times.

Exercise of directly registered warrants

Holders of warrants who have their holdings directly registered (holdings on a VP account) must notify the exercise of warrants by completing and submitting an application form for the exercise, so that the application form is received by the issuing agent, Nordic Issuing, no later than May 19, 2022.

The application form is available on the Company's, the issuing agent's and Redeye AB's respective websites (www.amniotics.com, www.nordic-issuing.se, www.redeye.se). Please note that payment for the new shares must be received by Nordic Issuing no later than May 19, 2022, in accordance with the instructions on the application form.

Trading in TO1

Holders who do not wish to exercise their warrants may sell them on Nasdaq First North Growth Market. The warrants are traded up to and including May 17, 2022, under the short name TO1 and with ISIN code SE0016101471. Warrants that are not exercised on May 19, 2022, at the latest or sold on May 17, 2022, at the latest will expire without value.

Outcome and delivery of new shares

The outcome of the exercise of warrants will be published via a press release on or around May 23, 2022. Shares that have been subscribed and paid for may be registered on the subscriber's securities depository as interim shares (IA) until registration of the issue has been completed with the Swedish Companies Registration Office, whereupon the interim shares automatically will be converted into ordinary shares in Amniotics.

Number of warrants and possible proceeds

The number of warrants amounts to 1,463,415. Upon full exercise of all warrants, Amniotics will receive approximately SEK 34.4 million before issuing costs. Upon full exercise of all warrants, the number of shares in Amniotics will increase with 1,463,415 shares to 17,529,745 shares and the share capital will increase with SEK 79,154.86 to SEK 948,168.81. This entails a dilution of approximately 8.35 percent based on the number of shares in Amniotics after full exercise of all warrants.

Complete terms and conditions for the warrants

Complete terms and conditions for the warrants are available on the Company's website, www.amniotics.com.

Advisers

Redeye AB acts as financial adviser and Nordic Issuing AB acts as the issuing agent in the rights issue.

For further information, please contact:

Kåre Engkilde
CEO, Amniotics AB
Phone: +46 (0) 723 27 85 20
Email: ke@amniotics.com

Johny Humaloja
CFO, Amniotics AB
Phone: +46 (0) 73 506 6856
Email: jh@amniotics.com

Amniotics AB (publ) 559024-6558
Medicon Village,
Scheelevägen 2, 223 63 Lund, Sweden

About Amniotics

Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics has also an, by Läkemedelsverket (Swedish MPA), approved Good Manufacturing Practice (GMP) facility to produce Advanced Therapy Medicinal Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs.

Amniotics (publ) has its headquarter in Lund, Sweden.

Amniotics Certified Adviser on First North is Redeye AB, certifiedadviser@redeye.se, telephone: +46 (0) 8 121 576 90.

The company is listed at Nasdaq First North Growth Market in Stockholm.

Learn more at www.amniotics.com.

IMPORTANT INFORMATION

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Amniotics. Invitation to the persons concerned to subscribe for units consisting of shares and warrants in Amniotics has only taken place through the prospectus that Amniotics published on June 14, 2021.

Attachments

The exercise period for Amniotics' warrants of series TO1 commences today